Phase I clinical evaluation of a new murine monoclonal antibody (mu-9) against colon-specific antigen-p for targeting gastrointestinal carcinomas

Abstract

These initial results support the need for further evaluation of Mu-9 immunoglobulin G and F(ab')2 for targeting gastrointestinal cancer for radioimmunotherapy.